---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-029582"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2024-04-03T23:59:59+00:00"
generated_at: "2026-06-04T02:53:57.318164+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BiomX reports FY2023 net loss $26.2M; completes APT acquisition and $50M financing

## Summary
- FY2023 net loss $26.2M vs $28.3M prior year; R&D expenses $16.7M.
- Completed acquisition of Adaptive Phage Therapeutics (March 2024), gaining BX211 for DFO.
- Closed $50M private placement led by Deerfield and AMR Action Fund; used to fund BX004 and BX211 through key data readouts.
- Cash, restricted cash and short-term deposits $15.9M at Dec 31, 2023; company states sufficient for 12 months post-financing.
- BX211 Phase 2 DFO trial enrolled 32 of 45 patients; topline results expected Q1 2025.

## SEC filing metadata
- accession: 0001213900-24-029582
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2024-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390024029582/0001213900-24-029582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390024029582/ea0203239-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-029582
- JSON: https://secwatch.observer/filing/0001213900-24-029582.json
- Plain text: https://secwatch.observer/filing/0001213900-24-029582.txt

## Key facts
- Earnings Releases
  BiomX Inc. reported financial results for fourth quarter and full year ended December 31, 2023.
  - Period: fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On April 3, 2024, BiomX Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739174/000121390024029582/0001213900-24-029582-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.